Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease [2]

Pediatric Allergy and Immunology

Volumn 19, Issue 2, 2008, Pages 186-187

  Khan, S ^a,b   Dore P C ^b   Sewell, W A C ^a,c  

^a SCUNTHORPE GENERAL HOSPITAL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF LINCOLN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; FC RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 5; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN ANTIBODY; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; EOSINOPHIL COUNT; GENE MUTATION; GENETIC POLYMORPHISM; GLYCOSYLATION; HUMAN; LETTER; MUCOCUTANEOUS LYMPH NODE SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING;

BIOLOGICAL MARKERS; CHILD; EOSINOPHILIA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 38849130653     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2007.00658.x     Document Type: Letter

References (10)

1. Kuo HC, Yang KD, Liang CD, et al. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Pediatr Allergy Immunol 2007 : 18 : 354 9.
2. Minami T, Suzuki H, Takeuchi T, Uemura S, Sugatani J, Yoshikawa N. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J Pediatr 2005 : 147 : 78 83.
3. von Gunten S, Vogel M, Schaub A, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2007 : 119 : 1005 11.
4. Kato M, Kimura H, Motegi Y, et al. Platelet-activating factor activates two distinct effector pathways in human eosinophils. J Immunol 2002 : 169 : 5252 9.
5. Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995 : 86 : 1437 43.
6. Stafforini DM, Numao T, Tsodikov A, et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest 1999 : 103 : 989 97.
7. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998 : 47 : 177 81.
8. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996 : 97 : 2784 91.
9. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 : 313 : 670 3.
10. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006 : 113 : 2606 12.